Literature DB >> 7596502

Surgical treatment of craniopharyngiomas: an evaluation of the transsphenoidal and pterional approaches.

G Maira1, C Anile, G F Rossi, C Colosimo.   

Abstract

Fifty-seven patients with craniopharyngiomas underwent a total of 64 operations. Their clinical follow-up ranged from 2.5 to 15.5 years, with a mean follow-up of 6.5 years. A transsphenoidal approach was used in 35 patients (61%), whereas 22 (39%) were operated on using a pterional approach (in 16 patients, the tumor was found in the suprasellar cisterns, and in 6, the tumor was found in the third ventricle and was removed passing through the lamina terminalis). Total removal of the tumor was achieved in 43 patients (75%). In six patients (11%), fragments of the capsule remained attached to the hypothalamus (subtotal removal), and, in eight patients (14%), the tumor was partially removed. No recurrence occurred in those patients in whom removal was total. Regrowth was observed in two patients (33%) in whom removal was subtotal and in two (25%) in whom removal was partial. Three of them underwent subsequent operations, and a total removal with good clinical outcome was achieved. All patients except two had good postoperative recovery. Twenty patients (35%) required hormonal replacement therapy. When transsphenoidal surgery was used, a total removal of the tumors was achieved in 23 (66%) of the patients. Good clinical outcome was seen in all 35 patients. Six patients (17%) required hormonal replacement therapy. When the pterional approach was used for tumors in the suprasellar cisterns, we achieved total removal of tumors in 15 patients (94%). Good clinical outcome was seen in 20 patients (91%). Eleven patients (50%) required hormonal replacement therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7596502     DOI: 10.1227/00006123-199504000-00012

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  19 in total

Review 1.  Neurogenic diabetes insipidus.

Authors:  John A Jane; Mary Lee Vance; Edward R Laws
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 2.  Craniopharyngioma surgery.

Authors:  Jürgen Honegger; Marcos Tatagiba
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 3.  Radiotherapy of other sellar lesions.

Authors:  N Karavitaki
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

4.  Long-term results of the surgical treatment of craniopharyngioma: the experience at the Policlinico Gemelli, Catholic University, Rome.

Authors:  M Caldarelli; L Massimi; G Tamburrini; M Cappa; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2005-07-02       Impact factor: 1.475

5.  Non-adenomatous sellar lesions: experience of a single centre and review of the literature.

Authors:  Maria Koutourousiou; George Kontogeorgos; Andreas Seretis
Journal:  Neurosurg Rev       Date:  2010-05-18       Impact factor: 3.042

6.  Craniopharyngioma: history.

Authors:  Garni Barkhoudarian; Edward R Laws
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

7.  Optimal treatment strategy for craniopharyngiomas based on long-term functional outcomes of recent and past treatment modalities.

Authors:  Takakazu Kawamata; Kosaku Amano; Yasuo Aihara; Osami Kubo; Tomokatsu Hori
Journal:  Neurosurg Rev       Date:  2010-01       Impact factor: 3.042

Review 8.  Craniopharyngiomas: our experience in Lyon.

Authors:  C Mottolese; A Szathmari; P Berlier; M Hermier
Journal:  Childs Nerv Syst       Date:  2005-06-22       Impact factor: 1.475

9.  Suprasellar pediatric craniopharyngioma resection via endonasal endoscopic approach.

Authors:  Zarina S Ali; Shih-Shan Lang; Ameet R Kamat; Nithin D Adappa; James N Palmer; Phillip B Storm; John Y K Lee
Journal:  Childs Nerv Syst       Date:  2013-05-24       Impact factor: 1.475

Review 10.  Surgery for craniopharyngioma.

Authors:  Michael Buchfelder; Sven-Martin Schlaffer; Fuhua Lin; Andrea Kleindienst
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.